First year report cards from the Merit-Based Incentive Payment System (MIPS): What will be learned and what next?. Rathi VK, McWilliams JM. JAMA. 2019.
Off-label treatment in otolaryngology: A cautionary tale. Rathi VK, Scangas GA, Gray ST. JAMA Otolaryngol Head Neck Surg. 2019.
Venture capital investment in therapeutic otolaryngologic devices, 2008–2017. Rathi VK, Murr AH, Feng AL, Tauscher JL, Naunheim MR, Kozin EK, Gray ST. JAMA Otolaryngol Head Neck Surg. 2019.
Post-operative care in an intermediate-level medical unit after head and neck microvascular free flap reconstruction. Yu PK, Sethi RKV, Rathi VK, et al. Laryngoscope Investig Otolaryngol. 2018.
CMS’ proposed overhaul of office visit payments: What’s the bottom line for otolaryngology? Rathi VK , Varvares MA, Naunheim MR. JAMA Otolaryngol Head Neck Surg. In press.
Utilization of steroid-eluting sinus stents between 2012 and 2017. *Rathi VK, *Gadkaree SK, Scangas GA, Naunheim MR, Metson B. JAMA Otolaryngol Head Neck Surg. JAMA Otolaryngol Head Neck Surg. 2018 Nov 15.
Bundled payments in otolaryngology: Early lessons from Arkansas. Rathi VK , Metson B, Varvares MA, Naunheim MR, Gray ST. Otolaryngol Head Neck Surg. Epub 2018.
Device safety. Otolaryngology clinics of North America. Rathi VK , Gray ST. Epub 2018.
The role of industry influence in sinus balloon dilation: Trends over time. Laryngoscope. 2018. Gadkaree SK, Rathi VK, Gottschalk E, et al. 2018 May 8.
The Merit-based Incentive Payment System (MIPS): A primer for otolaryngologists. Rathi VK, Naunheim MR, Varvares MA, Holmes K, Gagliano N, Hartnick CJ. Otolaryngol Head Neck Surg. 2018 May 1.
Patient preferences in subglottic stenosis treatment: A discrete choice experiment. Naunheim MR, Naunheim ML, Rathi VK, Franco RA, Shrime MG, Song PC. Otolaryngol Head Neck Surg. 2018;158(3):520–526.
Risk factors for thirty-day readmission following flap reconstruction of oncologic defects of the head and neck. Osborn HA, Rathi VK, Tjoa T, et al. Laryngoscope. 2018.
Industry sponsorship of research in otolaryngology: An examination of the centers for medicare & medicaid services open payments database. Rathi VK, Abt NB, Kozin ED, Naunheim MR, Gray ST. JAMA Otolaryngol Head Neck Surg. 2017 Aug 01;143(8):842–843.
US Food and Drug Administration clearance of moderate-risk otolaryngologic devices via the 510(k) process, 1997–2016. Rathi VK, Gadkaree SK, Ross JS, Kozin ED, Sethi RK, Naunheim MR, Puram SV, Gray ST. Otolaryngol Head Neck Surg. 2017 Aug 01;194599817721689.
What do patients want from otolaryngologists? A discrete choice experiment. Naunheim MR, Rathi VK, Naunheim ML, Alkire BC, Lam AC, Song PC, Shrime MG. Otolaryngol Head Neck Surg. 2017 Jun 01;194599817717662.
Incremental revisions across the life span of ophthalmic devices after initial Food and Drug Administration premarket approval, 1979–2015. Gopal AD, Rathi VK, Teng CC, Del Priore L, Ross JS. Ophthalmology. 2017 Aug; 124(8):1237–1246.
Clinical evidence supporting US Food and Drug Administration approval of otolaryngologic prescription drug indications, 2005–2014. Rathi VK, Wang B, Ross JS, Downing NS, Kesselheim AS, Gray ST. Otolaryngol Head Neck Surg. 2017 Apr; 156(4):683–692.
Clinical evidence supporting US Food and Drug Administration premarket approval of high-risk otolaryngologic devices, 2000–2014. Rathi VK, Wang B, Ross JS, Downing NS, Kesselheim AS, Gray ST. Otolaryngol Head Neck Surg. 2017 Feb; 156(2):285–288.
Commentary: Diagnostic devices in clinical trials have high stakes for patient care. Rathi VK, Krumholz HM, Ross JS. BMJ. 2016 Sep 28;354:i5197.
The FDA 515 initiative: Addressing the evidence gap for high-risk cardiovascular devices? Rathi VK, Kesselheim AS, Ross JS. JAMA Cardiology. 2016 May 1;1(2):117–8.
Publication of clinical studies supporting FDA premarket approval for high-risk cardiovascular devices between 2011 and 2013: A cross-sectional study. Phillips AT, Rathi VK, Ross JS. JAMA Intern Med. 2016 Apr 1;176(4):551–2.
How do orthopaedic devices change after their initial FDA premarket approval? Samuel AM, Rathi VK, Grauer JN, Ross JS. Clin Orthop Relat Res. 2016 Apr;474(4):1053–68.
Characteristics of clinical studies conducted over the total product life cycle of high-risk therapeutic medical devices receiving FDA premarket approval in 2010 and 2011. Rathi VK, Krumholz HM, Masoudi FA, Ross JS. JAMA. 2015 Aug 11;314(6):604–12.
Orthopaedic surgeons receive the most industry payments to physicians but large disparities are seen in sunshine act data. Samuel AM, Webb ML, Lukasiewicz AM, Bohl DD, Basques BA, Russo GS, Rathi VK, Grauer JN. Clin Orthop Relat Res. 2015 Oct;473(10):3297–306.
Postmarket modifications of high-risk therapeutic devices in otolaryngology cleared by the US Food and Drug Administration. Rathi VK, Ross JS, Samuel AM, Mehra S. Otolaryngol Head Neck Surg. 2015 Sep;153(3):400–8.
Industry ties in otolaryngology: Initial insights from the physician payment sunshine act. Rathi VK, Samuel AM, Mehra S. Otolaryngol Head Neck Surg. 2015 Jun;152(6):993–9.
Predictors of clinical trial data sharing: Exploratory analysis of a cross-sectional survey. Rathi VK, Strait KM, Gross CP, Hrynaszkiewicz I, Joffe S, Krumholz HM, Dzara K, Ross JS. Trials. 2014 Oct 2;15:384.
Association of genes with physiological functions by comparative analysis of pooled expression microarray data. Chen IB, Rathi VK, DeAndrade DS, Jay PY. Physiol Genomics. 2013 Jan 15;45(2):69–78.
Sharing of clinical trial data among trialists: A cross sectional survey. Rathi V, Dzara K, Gross CP, Hrynaszkiewicz I, Joffe S, Krumholz HM, Strait KM, Ross JS. BMJ. 2012. 2012;345:e7570.